Novel strategies in therapy of head and neck cancer

Current Cancer Drug Targets

Volumn 11, Issue 4, 2011, Pages 465-478

  Mehrotra, R ^a   Ibrahim, R ^b   Eckardt, A ^c   Driemel, O ^d   Singh, M ^a  

^a MLN MEDICAL COLLEGE   (India)

^b SAM HIGGINBOTTOM UNIVERSITY OF AGRICULTURE   (India)

^c LEIBNIZ UNIVERSITY HANNOVER   (Germany)

^d UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Chemotherapy; Head immunotherapy; Malignancy; Molecular; Neck; Photodynamic

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; IMMUNOLOGIC AGENT; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B INHIBITOR; VASCULOTROPIN INHIBITOR;

CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; HEAD AND NECK CANCER; HUMAN; MOLECULAR THERAPY; PHOTODYNAMIC THERAPY; REVIEW;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOTHERAPY; PHOTOCHEMOTHERAPY;

EID: 79955624379     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800911795538039     Document Type: Review

References (121)

1. Mehrotra, R.; Pandya, S.; Chaudhary, A. K.; Singh, M. Prevalence of oral premalignant and malignant lesions at a tertiary level hospital in Allahabad, India. Asian Pac. J. Cancer Prev. 2008, 9, 263-265.
2. Altekruse, S. F.; Kosary, C. L.; Krapcho, M.; Neyman, N.; Aminou, R.; Waldron, W.; Ruhl, J.; Howlader, N.; Tatalovich, Z.; Cho, H.; Mariotto, A.; Eisner, M. P.; Lewis, D. R.; Cronin, K.; Chen, H. S.; Feuer, E. J.; Stinchcomb, D. G.; Edwards, B. K. (eds). SEER Cancer Statistics Review, 1975-2007, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2007/, based on November 2009 SEER data submission, posted to the SEER web site, 2010.
3. Jemal, A.; Siegel, R.; Xu, J.; Ward, E. Cancer statistics 2010. CA: A Cancer J. Clin. 2010, 60, 277-300.
4. Chaudhary, A. K.; Singh, M.; Sundaram, S.; Mehrotra, R. Role of human papillomavirus and its detection in potentially malignant and malignant head and neck lesions: updated review. Head Neck Oncol. 2009, 1, 22.
5. Robbins, K. T.; Kumar, P.; Wong, F. S.; Hartsell, W. F.; Flick, P.; Palmer, R.; Weir, A. B. 3rd.; Neill, H. B.; Murry, T.; Ferguson, R.; Hanchett, C.; Vieira, F.; Bush, A.; Howell, S. B. Targeted chemoradiation for advanced head and neck cancer: Analysis of 213 patients. Head Neck 2000, 22, 687-693.
6. Fuwa, N.; Ito, Y.; Matsumoto, A.; Kamata, M.; Kodaira, T.; Furutani, K.; Sasaoka, M.; Kimura, Y.; Morita, K. A combination therapy of continuous superselective intraarterial carboplatin infusion and radiation therapy for locally advanced head and neck carcinoma. Phase I study. Cancer 2000, 89, 2099-2105.
7. Kovacs, A. F. Intra-arterial induction high-dose chemotherapy with cisplatin for oral and oropharyngeal cancer: long term results. Br. J. Cancer 2004, 90, 1323-1328.
8. Rasch, C. R.; Hauptmann, M.; Balm, A. J. Intra-arterial chemotherapy for head and neck cancer: is there a verdict? Cancer 2010 Oct 4. [Epub ahead of print]
9. Doweck, I.; Robbins, K. T.; Samant, S.; Vieira, F. Intra-arterial chemoradiation for T3-4 oral cavity cancer: Treatment outcomes in comparison to oropharyngeal and hypopharyngeal carcinoma. World J. Surg. Oncol. 2006, 6, 2.
10. van den Broek, G. B.; Balm, A. J.; van den Brekel, M. W.; Hauptmann, M.; Schornagel, J. H.; Rasch, C. R. Relationship between clinical factors and the incidence of toxicity after intraarterial chemoradiation for head and neck cancer. Radiother. Oncol. 2006, 81, 143-150.
11. Zuur, C. L.; Simis, Y. J.; Lansdaal, P. E.; Hart, A. A.; Schornagel, J. H.; Dreschler, W. A.; Rasch, C. R.; Balm, A. J. Ototoxicity in a randomized phase III trial of intra-arterial compared with intravenous cisplatin chemoradiation in patients with locally advanced head and neck cancer. J. Clin. Oncol. 2007, 25, 3759-3765.
12. Pignon, J. P.; Bourhis, J.; Domenge, C.; Designé, L. Chemotherapy added to locoregional treatment for head and neck squamous cell carcinoma: three meta-analyses of updated individual data. Lancet 2000, 35, 949-955.
13. Bernier, J.; Bentzen, S. M. Altered fractionation and combined radio-chemotherapy approaches: pioneering new opportunities in head and neck oncology. Eur. J. Cancer 2003, 39, 560-571.
14. Domenge, C.; Hill, C.; Lefebvre, J. L.; Raucourt, D.; Rhein, B.; Wibault, P.; Marandas, P.; Coche-Dequeant, B.; Stromboni-Luboinski, M.; Sancho-Garnier, H.; Luboinski, B.; French Groupe d'Etude des Tumeurs de la Tête et du Cou (GETTEC). Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. Br. J. Cancer 2000, 83, 1594-1598.
15. Adelstein, D. J. Redefining the role of induction chemotherapy in head and neck cancer. J. Clin. Oncol. 2008, 26, 3117-3119
16. Monnerat, C.; Faivre, S.; Temam, S.; Bourhis, J.; Raymond, E. End points for new agents in induction chemotherapy for locally advanced head and neck cancers. Ann. Oncol. 2002, 13, 995-1006.
17. Catimel, G.; Verweij, J.; Mattijssen, V.; Hanauske, A.; Piccart, M.; Wanders, J.; Franklin, H.; Bail, N.; Clavel, M.; Kaye, S. B. Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann. Oncol. 1994, 5, 533-537.
18. Forastiere, A. A.; Shank, D.; Neuberg, D.; Taylor S. G.; DeConti, R. C.; Adams, G. Final report of a phase II evaluation of paclitaxel in patients with advanced squamous carcinoma of the head and neck: an Eastern Cooperative oncology Group trial (PA390). Cancer 1998, 82, 2270-2274.
19. Couteau, C.; Chouaki, N.; Leyvraz, S.; Oulid-Aissa, D.; Lebecq, A.; Domenge, C.; Groult, V.; Bordessoule, S.; Janot, F.; De Forni, M.; Armand, J. P. A phase II study of docetaxel in patients with metastatic squamous cell carcinoma of the head and neck. Br. J. Cancer 1999, 81, 457-462.
20. Hitt, R.; Amador, M. L.; Quintela-Fandino M.; Jimeno, A.; del Val, O.; Hernando, S.; Cortes-Funes, H. Weekly docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Cancer 2006, 106, 106-111.
21. Shin, D. M.; Glisson, B. S.; Khuri, F. R.; Lippman, S. M.; Ginsberg, L.; Edward, J. R.; Papadimitrakopoulou, V.; Feng, L.; Francisco, M.; Garden, A.; Kies, M. S.; Myers, J.; Clayman, G.; Waun K. H. Phase II study of induction chemotherapy with paclitaxel, ifosfamide and carboplatin for patients with locally advanced squamous cell carcinoma of the head and neck. Cancer 2002, 95, 322-330.
22. Colevas, A. D.; Norris, C. M.; Tishler, R. B.; Fried, M. P.; Gomolin, H. I.; Amrein, P.; Nixon, A.; Lamb, C.; Costello, R.; Barton, J.; Read, R.; Adak, S.; Posner, M. R. Phase II trial of docetaxel, cisplatin, 5-fluorouracil, and leucovorin as induction for patients with squamous cell carcinoma of the head and neck. J. Clin. Oncol. 1999, 17, 3503-3511.
23. Schrijvers, D.; Van Herpen, C.; Kerger, J.; Joosens, E.; Van Laer C.; Awada, A.; Weyngaert, D.; Nguyen, H.; Bouder, C.; Castelijns, J. A.; Kaanders, J.; Mulder, P.; Vermorken, J. B. Docetaxel, cisplatin and 5-fluorouracil in patients with locally advanced unresectable head and neck cancer: a phase I-II feasibility study. Ann. Oncol. 2004, 15, 638-645.
24. Posner, M. R.; Glisson, B.; Frenette, G.; Al-Sarraf, M.; Colevas, A. D.; Norris, C. M.; Seroskie, J. D.; Shin, D. M.; Olivares, R.; Garay C. A. Multicenter phase I-II trial of deocetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck. J. Clin. Oncol. 2001, 19, 1096-1104.
25. Hitt, R.; Lopez-Pousa, A.; Martinez-Trufero, J.; Escrig, V.; Carles, J.; Rizo, A.; Isla, D.; Eugenia Vega, M.; Martí, J. L.; Lobo, F.; Pastor, P.; Valentí, V.; Belón, J.; Sánchez, M. A.; Chaib, C.; Pallarés, C.; Antón, A.; Cervantes, A.; Paz-Ares, L.; Cortés-Funes, H. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J. Clin. Oncol. 2005, 23, 8636-8645.
26. Posner, M. R.; Hershock, D. M.; Blajman, C. R.; Mickiewicz, E.; Winquist, E.; Gorbounova, V.; Tjulandin, S.; Shin, D. M.; Cullen, K.; Ervin, T. J.; Murphy, B. A. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N. Engl. J. Med. 2007, 357, 1705-1715.
27. Kies, M. S. Induction chemotherapy for squamous cancer of the head and neck. Curr. Oncol. Rep. 2007, 9 (2), 129-33.
28. Harrington, K.; Hingorani, M.; Tanay, M.; Matthews, J.; Newbold, K.; Renouf. L.; Goldsweig, H.; McNeish, I.; Coffin, R. S.; Nutting, C. A phase I/II dose escalation study of OncoVexGM-CSF and chemoradiotherapy in untreated stage III/IV squamous cell cancer of the head and neck Institute of Cancer Research. http://www.biovex.com/downloads/ASCO_2009_HnN.pdf
29. Rapidis, A. D.; Wolf, G. T. Immunotherapy of head and neck cancer: current and future considerations. J. Oncol. 2009, 346345.
30. Whiteside, T. L.; Letessier, E.; Hirabayashi, H.; Vitolo, D.; Bryant, J.; Barnes, L.; Snyderman, C.; Johnson, J. T.; Myers, E.; Herberman, R. B.; Rubin, J.; Kirkwood, J. M.; Vlock, D. R. Evidence for local and systemic activation of immune cells by peritumoural injections of interleukin 2 in patients with advanced squamous cell carcinoma of the head and neck. Cancer Res. 1993, 53, 5654-5662.
31. Goedegebuure, P. S.; Eberlein, T. J. The role of CD4+ tumourinfiltrating lymphocytes in human solid tumours. Immunol. Res. 1995, 14, 119-131.
32. Muraoka, K.; Okumura, K.; Kitajo, H.; Kato, H.; Arisue, M. Chemokine receptor expression in oral squamous cell carcinoma correlation with growth factor-and cytokine-mediated cell migration in vitro. Oral. Sci. Int. 2007, 4, 273-285.
33. Zlotnik, A.; Yoshie, O. Chemokines: a new classification system and their role in immunity. Immunity 2000, 12, 121-127.
34. Bacon, K.; Baggiolini, M.; Broxmeyer, H.; Horuk, R.; Lindley, I.; Mantovani, A.; Maysushima, K.; Murphy, P.; Nomiyama, H.; Oppenheim, J.; Rot, A.; Schall, T.; Tsang, M.; Thorpe, R.; Damme, J.; Wadhwa, M.; Yoshie, O.; Zlotnik, A.; Zoon, K. Chemokine/chemokine receptor nomenclature. J. Interferon Cytokine Res. 2002, 22, 1067-1068.
35. Shintani, S.; Ishikawa, T.; Nonaka, T.; Li, C.; Nakashiro, K.; Wong, T. W.; Hamakawa, H. Growth-regulated oncogene-1 expression is associated with angiogenesis and lymph node matastasis in human oral cancer. Oncology 2004, 66, 316-322.
36. Barrera, J. L.; Verastegui, E.; Meneses, A.; Zinser, J.; de la Garza, J.; Hadden, J. W. Combination immunotherapy of squamous cell carcinoma of the head and neck: a phase 2 trial. Arch. Otolaryngol. Head Neck Surg. 2000, 126, 345-351.
37. Tímár, J.; Ladányi, A.; Forster-Horváth, C, Lukits, J.; Döme, B.; Remenár, E.; Godény, M.; Kásler, M.; Bencsik, B.; Répássy, G.; Szabó, G.; Velich, N.; Suba, Z.; Elo, J.; Balatoni, Z.; Pócza, K.; Zemplén, B.; Chretien, P.; Talor, E. Neoadjuvant immunotherapy of oral squamous cell carcinoma modulates intratumoural CD4/CD8 ratio and tumour microenvironment: a multicenter phase II clinical trial. J. Clin. Oncol. 2005, 23, 3421-3432.
38. Okamoto, M.; Sato, M. Toll-like receptor-targeting immunotherapy for oral cancer. Oral Sci. Int. 2004, 1, 1-15.
39. Khurram, S. A.; Whawell, S. A.; Bingle, L.; Murdoch, C.; McCabe, B. M.; Farthing, P. M. Functional expression of the chemokine receptor XCR1 on oral epithelial cells. J. Pathol. 2010, 221 (2), 153-63.
40. Uchida, D.; Onoue, T.; Tomizuka, Y.; Begum, N. M.; Miwa, Y.; Yoshida, H.; Sato, M. Involvement of an autocrine stromal cell derived factor-1/CXCR4 system on the distant metastasis of human oral squamous cell carcinoma. Mol. Cancer Res. 2007, 5, 685-694.
41. Michaluart, P.; Abdallah, K. A.; Lima, F. D.; Smith, R.; Moysés, R. A.; Coelho, V.; Victora, G. D.; Socorro-Silva, A.; Volsi. E. C.; Zárate-Bladés, C. R.; Ferraz, A. R.; Barreto, A. K.; Chammas, M. C.; Gomes, R.; Gebrim, E.; Arakawa-Sugueno, L.; Fernandes, K. P.; Lotufo, P. A.; Cardoso, M. R.; Kalil, J.; Silva, C. L. Phase I trial of DNA-hsp65 immunotherapy for advanced squamous cell carcinoma of the head and neck Cancer Gene Ther. 2008, 15, 676-684.
42. Kawakami, M.; Kawakami, K.; Puri, R. K. Tumor regression mechanisms by IL-13 receptor-targeted cancer therapy involve apoptotic pathways. Int. J. Cancer. 2003, 103 (1), 45-52.
43. Mehrotra, R. Interleukin 13 is secreted by human head and neck tumours and does not modulate their growth in vitro. Indian J. Exp. Biol. 1998, 36, 805-7.
44. Davidson, H. C.; Leibowitz, M. S.; Lopez-Albaitero, A.; Ferris, R. L. Immunotherapy for head and neck cancer. Oral Oncol. 2009, 45, 747-751.
45. Kübler, A. C.; Scheer, M.; Zöller, J. E. Photodynamic therapy of head and neck cancer. Onkologie 2001, 24, 230-237
46. Seshadri, M.; Spernyak, J. A.; Mazurchuk, R.; Camacho, S. H.; Oseroff, A. R.; Cheney, R. T.; Bellnier, D. A. Tumour vascular response to photodynamic therapy and the antivascular agent 5,6-dimethylxanthenone-4-acetic acid: implications for combination therapy. Clin. Cancer Res. 2005, 11, 4241-4250.
47. Hopper, C.; Kübler, A.; Lewis, H.; Bing, T.; Putnam, G. mTHPCmediated photodynamic therapy for early oral squamous cell carcinoma. Int. J. Cancer 2004, 111, 138-146.
48. Wood, S.; Garg, A.; Bonass, W. A. Photodynamic Therapy of Oral Cancer Cell Lines Cell Death Mechanisms (IADR/AADR/CADR 87th General Session and Exhibition) April 1-4, 2009
49. th ed. 2010.
50. Dolmans, D. E.; Fukumura, D.; Jain, R. K. Photodynamic therapy for cancer. Nature Reviews Cancer 2003, 3 (5), 380-387
51. Wilson, B. C. Photodynamic therapy for cancer: Principles. Can. J. Gastroenterol. 2002, 16 (6), 393-396.
52. Vrouenraets, M. B.; Visser; G. W. M.; Snow, G. B.; van Dongen, G. A. Basic principles, applications in oncology and improved selectivity of photodynamic therapy. Anticancer Res. 2003, 23, 505-522.
53. Dougherty, T. J. An update on photodynamic therapy applications. J. Clin. Laser Med. Surg. 2002, 20 (1), 3-7.
54. Rigual, N. R.; Thankappan, K.; Cooper, M.; Sullivan, M. A.; Dougherty, T.; Popat, S. R.; Loree, T. R.; Biel, M. A.; Henderson, B. Photodynamic therapy for head and neck dysplasia and cancer. Arch. Otolaryngol. Head Neck Surg. 2009, 135 (8), 784-788.
55. Biel, M. A. Photodynamic therapy treatment of early oral and laryngeal cancers. Photochem. Photobiol. 2007, 83 (5), 1063-1068.
56. Wildeman, M. A.; Nyst, H. J.; Karakullukcu, B.; Tan, B. I. Photodynamic therapy in the therapy for recurrent/persistent nasopharyngeal cancer. Head Neck Oncol. 2009, 17, 1:40.
57. Stephenson, J. Researchers optimistic about sea change in cancer treatment. JAMA 2001, 285, 2841-2842.
58. Rowinsky, E. K. The pursuit of optimal outcomes in cancer therapy in a new age of rationally designed target-based anticancer agents. Drugs 2000, 60, 1-14.
59. Mehrotra, R.; Vasstrand, E. N.; Ibrahim, S. O. Recent advances in understanding carcinogenicity of oral squamous cell carcinoma; from basic molecular biology to latest genomics and proteomics findings. Cancer Genom. Proteom. 2004, 1, 283-294.
60. Hanahan, D.; Weinberg, R. A. The hallmarks of cancer. Cell 2000, 100, 57-70.
61. Lin, D. T.; Subbaramaiah, K.; Shah, J. P.; Dannenberg, A. J.; Boyle, J. O. Cyclooxygenase-2: a novel molecular target for the prevention and treatment of head and neck cancer. Head Neck 2002, 24, 792-799.
62. Masferrer, J. L.; Leahy, K. M.; Koki, A. T.; Zweifel, B. S.; Settle, S. L.; Woerner, B. M.; Edwards, D. A.; Flickinger, A. G.; Moore, R. J.; Seibert, K. Antiangiogenic and antitumour activities of cyclooxygenase-2 inhibitors. Cancer Res. 2000, 60, 1306-1311.
63. Buchanan, F. G.; Wang, D.; Bargiacchi, F.; DuBois, R. N. Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J. Biol. Chem. 2003, 278, 35451-35457.
64. Pai, R.; Soreghan, B.; Szabo, I. L.; Pavelka, M.; Baatar, D.; Tarnawski, A. S. Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat. Med. 2002, 8, 289-293.
65. Subbaramaiah, K.; Norton, L.; Gerald, W.; Dannenberg, A. J. Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3. J. Biol. Chem. 2002, 277, 18649-18657.
66. Mestre, J. R.; Subbaramaiah, K.; Sacks, P. G.; Schantz, S. P.; Tanabe, T.; Inoue, H.; Dannenberg, A. J. Retinoids suppress phorbol ester-mediated induction of cyclooxygenase-2. Cancer Res. 1997, 57, 1081-1085.
67. Zakar, T.; Mijovic, J. E.; Eyster, K. M.; Bhardwaj, D.; Olson, D. M. Regulation of prostaglandin H2 synthase-2 expression in primary human amnion cells by tyrosine kinase dependent mechanisms. Biochim. Biophys. Acta 1998, 391, 37-51.
68. Tortora, G.; Caputo, R.; Damiano, V.; Malisi, D.; Bianco, R.; Fontanini, G.; Veneziani, B. M.; De Placido, S. D.; Bianco, A. R.; Ciardiello, F. Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumour and antiangiogenic effect. Clin. Cancer Res. 2003, 9, 1566-1572.
69. Saba, N. F.; Choi, M.; Muller, S.; Shin, H. J.; Tighiouart, M.; Papadimitrakopoulou, V. A.; El-Naggar, A. K.; Khuri, F. R.; Chen, Z. G.; Shin, D. M. Role of cyclooxygenase-2 in tumor progression and survival of head and neck squamous cell carcinoma. Cancer Prev. Res. (Phila Pa). 2009, 2, 823-829.
70. Hao, Y.; Xie, T.; Korotcov, A.; Zhou, Y.; Pang, X.; Shan, L.; Ji, H.; Sridhar, R.; Wang, P.; Califano, J.; Gu. X. Salvianolic acid B inhibits growth of head and neck squamous cell carcinoma in vitro and in vivo via cyclooxygenase-2 and apoptotic pathways. Int. J. Cancer 2009, 124, 2200-2209.
71. Tominaga, O.; Hamelin, R.; Remvikos, Y.; Salmon, R. J.; Thomas, G. p53 from basic research to clinical applications. Crit. Rev. Oncol. 1992, 3, 257-282.
72. Shin, D. M.; Lee, J. S.; Lippman, S. M.; Lee, J.; Tu, Z. N.; Choi, G.; Heyne, K.; Shin, H. J. C.; Ro, J. Y.; Goepfert, H.; Hong, W. K.; Hittelman, W. N. p53 expressions: predicting recurrence and second primary tumours in head and neck squamous cell carcinoma. J. Natl. Cancer Inst. 1996, 88, 519-529.
73. Boyle, J. O.; Hakim, J.; Koch, W.; Riet, P.; Hruban, R. H.; Roa, R. A.; Correo, R.; Eby, Y. J.; Ruppert, J. M.; Sidransky, D. The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res. 1993, 53, 4477-4480.
74. Cabelguenne, A.; Blons, H.; de Waziers, I.; Carnot, F.; Houllier, A.M.; Soussi, T.; Brasnu, D.; Beaune, P.; Laccourreye, O.; Laurent-Puig, P. p53 alterations predict tumour response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: a prospective series. J. Clin. Oncol. 2000, 18, 1465-1473.
75. Rudin, C. M.; Cohen, E. E.; Papadimitrakopoulou, V. A.; Silverman, S.; Recant, W.; El-Naggar, A. K.; Stenson, K.; Lippman, S. M.; Hong, W. K.; Vokes, E. E. An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia. J. Clin. Oncol. 2003, 21, 4546-4552.
76. Khuri, F. R.; Nemunaitis, J.; Ganly, I.; Arseneau, J.; Tannock, I. F.; Rome. L.; Gore, M.; Ironside, J.; Macdougall, R. H.; Heise, C.; Randlev, B.; Gillenwater, A. M.; Bruso, P.; Kaye, S. B.; Hong, W. K.; Kirn, D. H. A controlled trial of intratumoural ONYX-015, a selectively replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat. Med. 2000, 6, 879-885.
77. Myers, J. N.; Holsinger, F. C.; Bekele, B. N.; Li. E.; Jasser, S. A.; Killion, J. J.; Fidler, I.J. Targeted molecular therapy for oral cancer with epidermal growth factor receptor blockade: a preliminary report. Arch. Otolaryngol. Head Neck Surg. 2002, 128, 875-879.
78. Bernier, J.; Bentzen, S. M.; Vermorken, J. B. Molecular therapy in head and neck oncology. Nat. Rev. Clin. Oncol. 2009, 6 (5), 266-77.
79. Knecht, R.; Peters, S.; Solbach, C.; Baghi, M.; Gstöttner, W.; Hambek. M. EGFR antibody-supplemented TPEchemotherapy. Preclinical investigations to a novel approach for head and neck cancer induction treatment. Anticancer Res. 2003, 23, 4789-4795.
80. Cohen, E. E.; Rosen, F.; Stadler, W. M.; Recant, W.; Stenson, K.; Huo, D.; Vokes, E. E. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J. Clin. Oncol. 2003, 21, 1980-1987.
81. Inoue, A.; Saijo, Y.; Maemondo, M.; Gomi, K.; Tokue, Y.; Kimura, Y.; Ebina, M.; Kikuchi, T.; Moriya, T.; Nukiwa, T. Severe acute interstitial pneumonia and gefitinib. Lancet 2003, 361, 137-139.
82. Grandis R. J.; Melhem, M. F.; Gooding, W. F.; Day, R.; Holst, V. A.; Wagener, M. M.; Drenning, S. D.; Tweardy, D. J. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J. Natl. Cancer Inst. 1998, 90, 824-832.
83. Magne, N.; Fischel, J. L.; Dubreuil, A.; Formento, P.; Marcié, S.; Lagrange, J. L.; Milano, G. Sequence-dependent effects of ZD 1839 (Iressa®) in combination with cytotoxic treatment in human head and neck cancer. Br. J. Cancer 2002, 86, 819-827.
84. Doss, H. H.; Greco, F. A.; Meluch, A. A.; Gray, J. R.; Spigel, D. R.; Shipley, D. L.; Barton, J. H.; Kuzur, M. E., Ramsey, S.; Lunin, S. D.; Hainsworth, J. D. Induction chemotherapy + gefitinib followed by concurrent chemotherapy/radiation therapy/gefitinib for patients with locally advanced squamous carcinoma of the head and neck: a phase I/II trial of the Minnie Pearl Cancer Research Network. J. Clin. Oncol. 2006, 24 (no.18S), 5543.
85. Savvides, P.; Agarwala, S. S.; Greskovich, J.; Argiris, A.; Bokar, J.; Cooney, M.; Hoppel, C.; Stepnick, D. W; Lavertu, P.; Remick S. Phase I study of the EGFR tyrosine kinase inhibitor erlotinib in combination with docetaxel and radiation in locally advanced squamous cell cancer of the head and neck (SCCHN). J Clin. Oncol. 2006, 24, No 18S, 5545.
86. Hamakawa, H.; Nakashiro, K.; Sumida, T.; Shintani, S.; Myers, J. N.; Takes, R. P.; Rinaldo, A.; Ferlito, A. Basic evidence of molecular targeted therapy for oral cancer and salivary gland cancer. Head Neck 2008, 30 (6), 800-809.
87. A multi-institutional phase II study of radiation and gw572016 (lapatinib) for patients with stage III-IV head and neck cancer who cannot tolerate concurrent chemoradiotherapy. Information obtained from Clinical Trials. gov on December 29, 2010. http://clinicaltrials.gov/ct2/show/NCT00490061
88. Holsinger, F. C.; Doan, D. D.; Jasser, S. A.; Swan, E. A.; Greenberg, J. S.; Schiff, B. A.; Bekele, B. N; Younes, M. N.; Bucana, C. D.; Fidler, I. J.; Myers, J. N. Epidermal growth factor receptor blockade potentiates apoptosis mediated by Paclitaxel and leads to prolonged survival in a murine model of oral cancer. Clin. Cancer Res. 2003, 9, 3183-3189.
89. Lorch, J. L.; Klessner, J. H.; Park, J. K.; Getsios, S.; Wu, Y. L.; Stack, M. S.; Green, K. J. Epidermal growth factor receptor inhibition promotes desmosome assembly and strengthens intercellular adhesion in squamous cell carcinoma cells. J. Biol. Chem. 2004, 279, 37191-37200.
90. Choe, M. S.; Zhang, X.; Shin, H. J.; Shin, D. M.; Chen, Z. G. Interaction between epidermal growth factor receptor-and cyclooxygenase 2-mediated pathways and its implications for the chemoprevention of head and neck cancer. Mol. Cancer Ther. 2005, 4 (9), 1448-55.
91. Bonner, J. A.; Harari, P. M.; Giralt, J.; Azarnia, N.; Shin, D. M.; Cohen, R. B.; Jones, C. U.; Sur, R.; Raben, D.; Jassem, J.; Ove, R.; Kies, M. S.; Baselga, J.; Youssoufian, H.; Amellal, N.; Rowinsky, E. K.; Ang, K. K. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 2006, 9, 354, 567-578.
92. Burtness, B.; Goldwasser, M.; Flood, W.; Mattar, B.; Forastiere, A.; Eastern Cooperative Oncology Group. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J. Clin. Oncol. 2005, 23 (34), 8646-86454
93. Vermorken, J. B.; Mesia, R.; Rivera, F.; Remenar, E.; Kawecki, A.; Rottey, S.; Erfan, J.; Zabolotnyy, D.; Kienzer, H. R.; Cupissol, D.; Peyrade, F.; Benasso, M.; Vynnychenko, I.; De Raucourt, D.; Bokemeyer, C.; Schueler, A.; Amellal, N.; Hitt, R. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N. Engl. J. Med. 2008, 359 (11), 1116-1127.
94. Johnson, F. M.; Saigal, B.; Talpaz, M.; Donato, N. J. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin. Cancer Res. 2005, 11, 6924-6932.
95. Brooks, H. D.; Glisson, B.; Bekele, B.; Ginsberg, L.; El-Naggar, A.; Culotta, K. S.; Takebe, N.; Wright, J.; Tran, H. T.; Papadimitrakopoulou, V. Phase 2 study of Dasatinib in the treatment of head and neck squamous cell carcinoma. Cancer 2010 Nov.29[Epub ahead of print]
96. Masuda, M.; Suzui, M.; Lim, J. T.; Weinstein, I. B. Epigallocatechin-3-gallate inhibits activation of HER-2/neu and downstream signaling pathways in human head and neck and breast carcinoma cells. Clin. Cancer Res. 2003, 9, 3486-3491.
97. Knight, S. D.; Parrish, C. A. Recent progress in the identification and clinical evaluation of inhibitors of the mitotic kinesin KSP. Curr. Top. Med. Chem. 2006, 8, 888-904.
98. Ma, W. W.; Adjei, A. A. Novel agents on the horizon for cancer therapy. CA Cancer J. Clin. 2009, 59, 111-137.
99. Jin, H.; Varner, J. Integrins: roles in cancer development and as treatment targets. Br. J. Cancer 2004, 90, 561-565
100. Ramos, D. M.; But, M.; Regezi, J.; Schmidt, B. L.; Atakilit, A.; Dang, D.; Ellis, D.; Jordan, R.; Li, X. Expression of integrin beta 6 enhances invasive behavior in oral squamous cell carcinoma. Matrix Biol. 2002, 21, 297-307.
101. Li, X.; Yang, Y.; Hu, Y.; Dang, D.; Regezi, J.; Schmidt, B. L.; Atakilit, A.; Chen, B.; Ellis, D.; Ramos, D. M. Alphavbeta6-Fyn Signaling promotes oral cancer progression. J. Biol. Chem. 2003, 278, 41646-41653.
102. Nelson, K.; Helmstaedter, V.; Moreau, C.; Lage, H. Estradiol, tamoxifen and ICI 182,780 alter α3 and β1 integrin expression and laminin-1 adhesion in oral squamous cell carcinoma cell cultures. Oral Oncol. 2007, 44, 94-99.
103. 6 integrin in oral leukoplakia. Br. J. Cancer 2000, 82, 1433-1440.
104. Rosato, R. R.; Grant, S. Histone deacetylase inhibitors in cancer therapy. Cancer Biol. Ther. 2003, 2, 30-37.
105. Piekarz, R.; Bates, S. A review of depsipeptide and other histone deacetylase inhibitors in clinical trials. Curr. Pharm. Des. 2004, 10, 2289-2298.
106. Shen, J.; Huang, C.; Jiang, L.; Gao, F.; Wang, Z.; Zhang, Y.; Bai, J.; Zhou, H.; Chen, Q. Enhancement of cisplatin induced apoptosis by suberoylanilide hydroxamic acid in human oral squamous cell carcinoma cell lines. Biochem. Pharmacol. 2007, 73, 1901-1909.
107. Blumenschein, G. R. Jr.; Kies, M. S.; Papadimitrakopoulou, V. A.; Lu, C.; Kumar, A. J.; Ricker, J. L.; Chiao, J. H.; Chen, C.; Frankel, S. R. Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer. Invest. New Drugs 2008, 26, 81-87.
108. Gillenwater, A. M.; Zhong, M.; Lotan, R. Histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis through both mitochondrial and Fas (Cd95) signaling in head and neck squamous carcinoma cells. Mol. Cancer Ther. 2007, 6 (11), 2967-75.
109. Shang, Z. J.; Li, Z. B.; Li, J. R. VEGF is up-regulated by hypoxic stimulation and related to tumour angiogenesis and severity of disease in oral squamous cell carcinoma: in vitro and in vivo studies. Int. J. Oral Maxillofac. Surg. 2006, 35, 533-538.
110. Liang, X.; Yang, D.; Hu, J.; Hao, X.; Gao, J.; Mao, Z. Hypoxia inducible factor-alpha expression correlates with vascular endothelial growth factor-C expression and lymphangiogenesis/angiogenesis in oral squamous cell carcinoma. Anticancer Res. 2006, 28, 1659-1666.
111. Melillo, G. Inhibiting hypoxia-inducible factor 1 for cancer therapy. Mol. Cancer Res. 2006, 4, 601-605.
112. Savvides, P.; Greskovich, J.; Bokar, J.; Stepnick, D. W.; Fu, F.; Johnson, C.; Patel, J.; Wasman, S.; Remick, S.; Lavertu, P. Phase II study of bevacizumab in combination with docetaxel and radiation in locally advanced squamous cell cancer of the head and neck (SCCHN). J. Clin. Oncol. 2007, 25 (No. 18S), 6068.
113. Cohen, E. E.; Davis, D. W.; Karrison, T. G.; Seiwert, T. Y.; Wong, S. J.; Nattam, S.; Kozloff, M. F., Clark, J. I.; Yan, D. H.; Liu, W.; Pierce, C.; Dancey, J. E.; Stenson, K.; Blair, E.; Dekker, A.; Vokes, E. E. Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol. 2009, 10, 247-57.
114. Fujita, K.; Sano, D.; Kimura, M.; Yamashita, Y.; Kawakami, M.; Ishiguro, Y.; Nishimura, G.; Matsuda, H.; Tsukuda, M. Antitumour effects of bevacizumab in combination with paclitaxel on head and neck squamous cell carcinoma. Oncol. Rep. 2007, 18, 47-51.
115. Bussink, J.; Kogel, A. J.; van der Kogel, A. J.; Kaanders, J. H. Activation of the PI3-K/ AKT pathway and implications for radioresistance mechanisms in head and neck cancer. Lancet Oncol. 2006, 9, 288-296.
116. Amornphimoltham, P.; Patel, V.; Sodhi, A.; Nikitakis, N. G.; Sauk, J. J.; Sausvill, E. A.; Molinolo, A. A.; Gutkind, J. S. Mammalian Target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck. Cancer Res. 2005, 65, 9953-9961.
117. Nathan, C. O.; Amirghahari, N.; Rong, X.; Giordano, T.; Sibley, D.; Nordberg, M.; Glass, J.; Agarwal, A.; Caldito, G. Mammalian target of rapamycin inhibitors as possible adjuvant therapy for microscopic residual disease in head and neck squamous cell cancer. Cancer Res. 2007, 67, 2160-2168.
118. Johnson, T. L.; Lai, M. B.; Lai, J. C.; Bhushan, A. Inhibition of cell proliferation and MAP kinase and Akt pathways in oral squamous cell carcinoma by genistein and biochanin A. Evid. Based Complement Alternat. Med. 2008, 7 (3), 351-358.
119. Younis, R. H.; Schneider, A. Metformin inhibits mTOR Pathway in HNSCC cells through REDD1 upregulation; IADR General Session Miami, Florida, 1-4 April 2009; University of Maryland at Baltimore, Baltimore, MD http://iadr.confex.com/iadr/2009miami/webprogram/Paper118239.html
120. Sharma, H.; Sen, S.; Singh, N. Molecular pathways in the chemosensitization of cisplatin by quercetin in human head and neck cancer. Cancer Biol. Ther. 2005, 4, 949-55.
121. Ridge, J. A.; Glisson, B. S.; Lango, M. N.; Feigenberg, S. In: Head and Neck Tumors. Cancer Management: A Multidisciplinary Approach. Medical, Surgical & Radiation Oncology, Pazdur, R.; Wagman, L. D.; Camphausen, K. A.; Hoskins, W. J. Eds. UBM Medica, 12th ed. 2009. Chapter 1